These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model. Cadroy Y; Houghten RA; Hanson SR J Clin Invest; 1989 Sep; 84(3):939-44. PubMed ID: 2760221 [TBL] [Abstract][Full Text] [Related]
23. In vivo evaluation of antiplatelet agents in gerbil model of carotid artery thrombosis. Nishimura H; Naritomi H; Iwamoto Y; Tachibana H; Sugita M Stroke; 1996 Jun; 27(6):1099-103; discussion 1104. PubMed ID: 8650721 [TBL] [Abstract][Full Text] [Related]
24. The use of prostaglandins as local antithrombotic agents in microvascular surgery. Leung PC; Chan MY; Roberts MB Br J Plast Surg; 1981 Jan; 34(1):38-40. PubMed ID: 7006722 [TBL] [Abstract][Full Text] [Related]
25. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial. Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699 [TBL] [Abstract][Full Text] [Related]
26. Effect of a synthetic peptide corresponding to residues 313 to 320 of the alphaIIb subunit of the human platelet integrin alphaIIbbeta3 on carotid artery thrombosis in rabbits. Papamichael ND; Stathopoulou EM; Roussa VD; Tsironis LD; Kotsia AP; Stanica RM; Moussis V; Tsikaris V; Katsouras CS; Tselepis AD; Michalis LK J Pharmacol Exp Ther; 2009 May; 329(2):634-40. PubMed ID: 19244095 [TBL] [Abstract][Full Text] [Related]
27. Tripeptide SQL Inhibits Platelet Aggregation and Thrombus Formation by Affecting PI3K/Akt Signaling. Su XL; Su W; He ZL; Ming X; Kong Y J Cardiovasc Pharmacol; 2015 Sep; 66(3):254-60. PubMed ID: 25923322 [TBL] [Abstract][Full Text] [Related]
28. The role of various antithrombotic agents in microvascular surgery. Buckley RC; Davidson SF; Das SK Br J Plast Surg; 1994 Jan; 47(1):20-3. PubMed ID: 8124561 [TBL] [Abstract][Full Text] [Related]
29. The pyrrolidinoindoline alkaloid Psm2 inhibits platelet aggregation and thrombus formation by affecting PI3K/Akt signaling. Su XL; Su W; Wang Y; Wang YH; Ming X; Kong Y Acta Pharmacol Sin; 2016 Sep; 37(9):1208-17. PubMed ID: 27424653 [TBL] [Abstract][Full Text] [Related]
30. Effect of ticlopidine on platelet aggregation, adherence to damaged vessels, thrombus formation and platelet survival. Cattaneo M; Winocour PD; Somers DA; Groves HM; Kinlough-Rathbone RL; Packham MA; Mustard JF Thromb Res; 1985 Jan; 37(1):29-43. PubMed ID: 3983900 [TBL] [Abstract][Full Text] [Related]
31. [Experimental evaluation of low-dose aspirin used in microvascular surgery]. An ZQ; Gu YD; Zhong GR Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2000 May; 14(3):145-8. PubMed ID: 12080850 [TBL] [Abstract][Full Text] [Related]
32. Antithrombotic management with a stable prostacyclin analogue during extracorporeal circulation. Maurin N Contrib Nephrol; 1991; 93():205-9. PubMed ID: 1802582 [No Abstract] [Full Text] [Related]
33. Effect of dipfluzine on platelet aggregation and thrombus formation. Wang YL; He RR Zhongguo Yao Li Xue Bao; 1994 Sep; 15(5):443-6. PubMed ID: 7717072 [TBL] [Abstract][Full Text] [Related]
34. Acute thrombogenicity of arterial prostheses exposed to reduced blood flow in dogs: effects of heparin, aspirin, and prostacyclin. Merhi Y; Bernier J; Marois Y; Guidoin R J Cardiovasc Pharmacol; 1995 Jul; 26(1):1-5. PubMed ID: 7564348 [TBL] [Abstract][Full Text] [Related]
35. Cicaprost, an orally active prostacyclin analogue: its effects on platelet aggregation and skin blood flow in normal volunteers. Belch JJ; McLaren M; Lau CS; Mackay IR; Bancroft A; McEwen J; Thompson JM Br J Clin Pharmacol; 1993 Jun; 35(6):643-7. PubMed ID: 8329292 [TBL] [Abstract][Full Text] [Related]
36. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo. Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956 [TBL] [Abstract][Full Text] [Related]
37. The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species. Nishio S; Matsuura H; Kanai N; Fukatsu Y; Hirano T; Nishikawa N; Kameoka K; Umetsu T Jpn J Pharmacol; 1988 May; 47(1):1-10. PubMed ID: 2842529 [TBL] [Abstract][Full Text] [Related]
38. In vivo interaction of prostacyclin with an inhibitor of cyclic nucleotide phosphodiesterase, HL 725. Darius H; Lefer AM; Leprán I; Smith JB Br J Pharmacol; 1985 Mar; 84(3):735-41. PubMed ID: 2985163 [TBL] [Abstract][Full Text] [Related]
39. De-aggregatory action of prostacyclin in vivo and its enhancement by theophylline. Gryglewski RJ; Korbut R; Ocetkiewicz A Prostaglandins; 1978 Apr; 15(4):637-44. PubMed ID: 353903 [TBL] [Abstract][Full Text] [Related]
40. Carbacyclin--a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Whittle BJ; Moncada S; Whiting F; Vane JR Prostaglandins; 1980 Apr; 19(4):605-27. PubMed ID: 6992234 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]